UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Journal of hepatology, 2019-05, Vol.70 (5), p.1019-1023

2019

Link zum Volltext

Verfügbarkeit prüfen

A not so easy genotype—striking regional differences in SOF/RBV treatment responses in HCV GT2

Liver international, 2017-08, Vol.37 (8), p.1253-1254

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Journal of hepatology, 2017-11, Vol.67 (5), p.918-924

2017

Link zum Volltext

Verfügbarkeit prüfen

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Journal of hepatology, 2018-04, Vol.68 (4), p.663-671

2018

Link zum Volltext

Verfügbarkeit prüfen

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

Journal of viral hepatitis, 2021-10, Vol.28 (10), p.1474-1483

2021

Link zum Volltext

Verfügbarkeit prüfen

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry

Liver international, 2021-05, Vol.41 (5), p.949-955

2021

Link zum Volltext

Verfügbarkeit prüfen

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

Liver international, 2020-03, Vol.40 (3), p.539-548

2020

Link zum Volltext

Verfügbarkeit prüfen

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)

Zeitschrift fur Gastroenterologie, 2023-05, Vol.61 (5), p.489

2023

Link zum Volltext

Verfügbarkeit prüfen

Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”

Journal of hepatology, 2017-08, Vol.67 (2), p.420-422

2017

Link zum Volltext

Verfügbarkeit prüfen

Treatment of viral hepatitis in HIV–coinfected patients–adverse events and their management

Journal of hepatology, 2006, Vol.44 (1 Suppl), p.S114-S118

Mauss, Stefan

2006

Link zum Volltext

Verfügbarkeit prüfen

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry

Journal of viral hepatitis, 2020-07, Vol.27 (7), p.690-698

2020

Link zum Volltext

Verfügbarkeit prüfen

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

Liver international, 2017-02, Vol.37 (2), p.205-211

2017

Link zum Volltext

Verfügbarkeit prüfen

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Journal of hepatology, 2020-03, Vol.72 (3), p.431-440

2020

Link zum Volltext

Verfügbarkeit prüfen

Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study

Clinical gastroenterology and hepatology, 2023-03, Vol.21 (3), p.713-722.e3

2023

Link zum Volltext

Verfügbarkeit prüfen

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

Journal of viral hepatitis, 2021-11, Vol.28 (11), p.1660-1664

2021

Link zum Volltext

Verfügbarkeit prüfen

Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection

Liver international, 2020-12, Vol.40 (12), p.2978-2981

2020

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany

Digestive diseases and sciences, 2016-10, Vol.61 (10), p.3061-3071

2016

Link zum Volltext

Verfügbarkeit prüfen

Current recommendations for the treatment of chronic hepatitis C

Zeitschrift fur Gastroenterologie, 2014-10, Vol.52 (10), p.1185

2014

Link zum Volltext

Verfügbarkeit prüfen

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

Liver international, 2018-11, Vol.38 (11), p.1906-1910

2018

Link zum Volltext

Verfügbarkeit prüfen

4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)

Zeitschrift fur Gastroenterologie, 2019-01, Vol.57 (1), p.27

2019

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C

Zeitschrift fur Gastroenterologie, 2019-02, Vol.57 (2), p.139

2019

Link zum Volltext

Verfügbarkeit prüfen

Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries

Zeitschrift fur Gastroenterologie, 2021-03, Vol.59 (3), p.241

2021

Link zum Volltext

Verfügbarkeit prüfen

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Journal of viral hepatitis, 2019-02, Vol.26 (2), p.224-230

2019

Link zum Volltext

Verfügbarkeit prüfen

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

Zeitschrift fur Gastroenterologie, 2019-05, Vol.57 (5), p.584

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 29

Suche als RSS-Feed

Aktive Filter

KollektionEZB Electronic Journals Library

KollektionIngentaConnect Journals

KollektionTaylor & Francis:Master (3349 titles)

ThemaGastroenterology & Hepatology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(29)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Humans
(19)
Hepatitis C
(16)
Male
(13)
Female
(12)
Hepatitis
(11)
Middle Aged
(11)
Antiviral Agents - Therapeutic Use
(9)
Hepatitis C, Chronic - Drug Therapy
(9)
Patients
(9)
Adult
(8)
Cirrhosis
(8)
Antiviral Agents
(7)
Liver
(7)
Prospective Studies
(7)
Registries
(7)
Treatment Outcome
(7)
Antiviral Agents - Administration & Dosage
(6)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

A not so easy genotype—striking regional differences in SOF/RBV treatment responses in HCV GT2

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)

Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”

Treatment of viral hepatitis in HIV–coinfected patients–adverse events and their management

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany

Current recommendations for the treatment of chronic hepatitis C

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)

Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C

Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries

Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance‐associated substitutions

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

Aktive Filter

Suchergebnisse filtern